CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Inari Medical, Inc. - NARI CFD

Market is not available at the moment

Market information is presented
as of 2023-09-21

  • Summary
Trading Conditions
Spread -
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Inari Medical Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* N/A
Open* N/A
1-Year Change* N/A
Day's Range* N/A
52 wk Range 52.59-83.84
Average Volume (10 days) 475.88K
Average Volume (3 months) 16.03M
Market Cap 3.62B
P/E Ratio -100.00K
Shares Outstanding 57.35M
Revenue 439.15M
EPS -0.30
Dividend (Yield %) N/A
Beta 1.01
Next Earnings Date Oct 31, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Date Close Change Change (%) Open High Low

Inari Medical, Inc. Events

Time (UTC) Country Event
Tuesday, October 31, 2023

Time (UTC)

10:59

Country

US

Event

Q3 2023 Inari Medical Inc Earnings Release
Q3 2023 Inari Medical Inc Earnings Release

Forecast

-

Previous

-
Monday, February 26, 2024

Time (UTC)

10:59

Country

US

Event

Q4 2023 Inari Medical Inc Earnings Release
Q4 2023 Inari Medical Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 383.471 276.984 139.67 51.1289 6.82877
Revenue 383.471 276.984 139.67 51.1289 6.82877
Cost of Revenue, Total 44.506 24.757 12.971 5.81874 1.28049
Gross Profit 338.965 252.227 126.699 45.3102 5.54828
Total Operating Expense 411.57 266.14 121.899 50.5326 15.9682
Selling/General/Admin. Expenses, Total 288.545 187.776 88.505 37.1533 10.6979
Research & Development 74.221 51.018 18.399 7.2199 3.98975
Operating Income -28.099 10.844 17.771 0.59633 -9.13938
Interest Income (Expense), Net Non-Operating 1.558 -0.141 -0.651 -0.83135 -0.79509
Other, Net 0.356 -0.018 -3.331 -0.95681 -0.21821
Net Income Before Taxes -26.185 10.685 13.789 -1.19183 -10.1527
Net Income After Taxes -29.267 9.84 13.789 -1.19183 -10.1527
Net Income Before Extra. Items -29.267 9.84 13.789 -1.19183 -10.1527
Net Income -29.267 9.84 13.789 -1.19183 -10.1527
Income Available to Common Excl. Extra. Items -29.267 9.84 13.789 -1.19183 -10.1527
Income Available to Common Incl. Extra. Items -29.267 9.84 13.789 -1.19183 -10.1527
Diluted Net Income -29.267 9.84 13.789 -1.19183 -10.1527
Diluted Weighted Average Shares 52.8377 55.5942 49.2516 46.0808 46.0808
Diluted EPS Excluding Extraordinary Items -0.5539 0.177 0.27997 -0.02586 -0.22032
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -0.5539 0.177 0.29794 -0.01882 -0.21968
Depreciation / Amortization 4.298 2.589 1.139 0.016
Unusual Expense (Income) 0.885 0.32462
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 119.005 116.167 107.771 96.204 92.744
Revenue 119.005 116.167 107.771 96.204 92.744
Cost of Revenue, Total 13.844 13.741 13.128 11.064 10.347
Gross Profit 105.161 102.426 94.643 85.14 82.397
Total Operating Expense 120.515 121.505 113.662 106.002 102.072
Selling/General/Admin. Expenses, Total 84.454 84.606 79.116 74.886 72.186
Research & Development 21.085 22.064 20.412 19.105 18.569
Depreciation / Amortization 1.132 1.094 1.006 0.947 0.97
Operating Income -1.51 -5.338 -5.891 -9.798 -9.328
Interest Income (Expense), Net Non-Operating 4.508 4.105 0.896 0.544 0.141
Other, Net 0.026 0.039 0.187 -0.059 0.252
Net Income Before Taxes 3.024 -1.194 -4.808 -9.313 -8.935
Net Income After Taxes 2.085 -2.218 -5.798 -10.153 -10.187
Net Income Before Extra. Items 2.085 -2.218 -5.798 -10.153 -10.187
Net Income 2.085 -2.218 -5.798 -10.153 -10.187
Income Available to Common Excl. Extra. Items 2.085 -2.218 -5.798 -10.153 -10.187
Income Available to Common Incl. Extra. Items 2.085 -2.218 -5.798 -10.153 -10.187
Diluted Net Income 2.085 -2.218 -5.798 -10.153 -10.187
Diluted Weighted Average Shares 58.4963 54.756 53.6927 53.4916 53.1838
Diluted EPS Excluding Extraordinary Items 0.03564 -0.04051 -0.10798 -0.18981 -0.19154
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.03564 -0.04051 -0.10798 -0.18981 -0.19154
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 422.905 245.198 205.673 39.4084 25.9644
Cash and Short Term Investments 326.401 176.1 164.21 23.6393 21.8337
Cash & Equivalents 60.222 92.752 114.229 23.6393 21.8337
Total Receivables, Net 58.611 42.351 28.008 11.3018 2.2295
Accounts Receivable - Trade, Net 58.611 42.351 28.008 11.3018 2.2295
Total Inventory 32.581 21.053 10.597 3.95321 1.09334
Prepaid Expenses 5.312 5.694 2.808 0.46408 0.75786
Other Current Assets, Total 0.05 0.05 0.05
Total Assets 504.152 311.542 214.092 44.5466 26.9015
Property/Plant/Equipment, Total - Net 72.358 61.38 7.498 3.33112 0.91996
Property/Plant/Equipment, Total - Gross 81.186 66.161 9.531 4.61026 1.98083
Accumulated Depreciation, Total -8.828 -4.781 -2.033 -1.27914 -1.06087
Other Long Term Assets, Total 0.589 0.981 0.921 1.80706 0.01708
Total Current Liabilities 56.174 42.513 13.838 8.8702 2.12785
Accounts Payable 7.659 6.541 3.047 2.5488 0.71409
Accrued Expenses 48.515 35.972 10.791 6.32139 1.41376
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 87.15 72.333 13.838 29.5202 12.1768
Total Long Term Debt 0 0 0 19.4807 9.83641
Long Term Debt 0 19.4807 9.83641
Other Liabilities, Total 30.976 29.82 0 1.16934 0.21253
Total Equity 417.002 239.209 200.254 15.0264 14.7247
Redeemable Preferred Stock 0 54.1702 54.1702
Common Stock 0.054 0.05 0.049 0.0096 0.00901
Additional Paid-In Capital 462.949 257.144 227.624 2.05837 1.42695
Retained Earnings (Accumulated Deficit) -46.85 -17.583 -27.423 -41.2118 -40.1235
Other Equity, Total 0.849 -0.379 0.004 0 -0.75798
Total Liabilities & Shareholders’ Equity 504.152 311.542 214.092 44.5466 26.9015
Total Common Shares Outstanding 54.0217 50.3134 49.2516 46.0808 46.0808
Short Term Investments 266.179 83.348 49.981
Long Term Investments 8.3 3.983
Unrealized Gain (Loss) -0.023
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 425.606 422.905 410.571 411.338 413.339
Cash and Short Term Investments 328.446 326.401 319.233 330.496 338.712
Cash & Equivalents 56.562 60.222 83.528 79.724 186.556
Short Term Investments 271.884 266.179 235.705 250.772 152.156
Total Receivables, Net 55.719 58.611 54.059 49.171 44.95
Accounts Receivable - Trade, Net 55.719 58.611 54.059 49.171 44.95
Total Inventory 36.499 32.581 29.67 26.674 23.828
Prepaid Expenses 4.942 5.312 7.609 4.997 5.849
Other Current Assets, Total
Total Assets 506.534 504.152 487.819 484.262 484.109
Property/Plant/Equipment, Total - Net 71.844 72.358 71.142 66.729 64.554
Property/Plant/Equipment, Total - Gross 81.997 81.186 79.165 73.641 70.354
Accumulated Depreciation, Total -10.153 -8.828 -8.023 -6.912 -5.8
Other Long Term Assets, Total 9.084 8.889 6.106 6.195 6.216
Total Current Liabilities 48.34 56.174 42.343 40.984 35.58
Accounts Payable 7.352 7.659 6.035 4.748 6.066
Accrued Expenses 40.988 48.515 36.308 36.236 29.514
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 79.798 87.15 72.72 70.484 65.297
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 31.458 30.976 30.377 29.5 29.717
Total Equity 426.736 417.002 415.099 413.778 418.812
Common Stock 0.057 0.054 0.053 0.053 0.053
Additional Paid-In Capital 475.754 462.949 457.043 445.807 440.238
Retained Earnings (Accumulated Deficit) -49.068 -46.85 -41.052 -30.899 -20.712
Other Equity, Total -0.007 0.849 -0.945 -1.183 -0.767
Total Liabilities & Shareholders’ Equity 506.534 504.152 487.819 484.262 484.109
Total Common Shares Outstanding 57.0837 54.0217 53.5953 53.3058 53.0229
Long Term Investments 0 0 0 0
Redeemable Preferred Stock 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -29.267 9.84 13.789 -1.19183 -10.1527
Cash From Operating Activities -13.972 25.486 1.912 -4.9359 -10.8921
Cash From Operating Activities 4.673 3.034 1.385 0.61352 0.28305
Non-Cash Items 32.09 26.912 7.907 1.9017 0.49788
Cash Taxes Paid 3.417 0.472 0.154 0.01381 0.01567
Cash Interest Paid 0.151 0.151 0.999 0.80993 0.74722
Changes in Working Capital -21.468 -14.3 -21.169 -6.2593 -1.52036
Cash From Investing Activities -195.216 -51.022 -55.437 -3.14414 -0.7527
Capital Expenditures -9.951 -13.645 -5.46 -3.14414 -0.7527
Cash From Financing Activities 177.138 4.073 144.115 10.2235 26.7577
Financing Cash Flow Items -6.489 -2.354 -0.467 0.23632 -0.25616
Issuance (Retirement) of Stock, Net 183.627 6.427 164.832 0.12721 27.0139
Issuance (Retirement) of Debt, Net 0 0 -20.25 9.86 0
Net Change in Cash -32.53 -21.865 90.59 2.14349 15.1129
Other Investing Cash Flow Items, Total -185.265 -37.377 -49.977
Foreign Exchange Effects -0.48 -0.402
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -2.218 -29.267 -23.469 -13.316 -3.129
Cash From Operating Activities -2.013 -13.972 -25.227 -12.161 -9.1
Cash From Operating Activities 1.348 4.673 3.43 2.26 1.063
Non-Cash Items 8.279 32.09 23.346 15.082 7.274
Cash Taxes Paid 0.104 3.417 3.085 2.297 0.089
Cash Interest Paid 0.032 0.151 0.112 0.075 0.037
Changes in Working Capital -9.422 -21.468 -28.534 -16.187 -14.308
Cash From Investing Activities -4.043 -195.216 -161.969 -175.371 -73.511
Capital Expenditures -0.964 -9.951 -8.173 -5.864 -2.745
Other Investing Cash Flow Items, Total -3.079 -185.265 -153.796 -169.507 -70.766
Cash From Financing Activities 2.466 177.138 178.827 174.947 176.542
Financing Cash Flow Items -1.932 -6.489 -4.599 -3.375 -1.624
Issuance (Retirement) of Stock, Net 4.398 183.627 183.426 178.322 178.166
Issuance (Retirement) of Debt, Net 0
Foreign Exchange Effects -0.07 -0.48 -0.855 -0.443 -0.127
Net Change in Cash -3.66 -32.53 -9.224 -13.028 93.804

Inari Medical, Inc. Company profile

About Inari Medical Inc

Inari Medical, Inc. is a medical device company. The Company operates through the development and commercialization of invasive mechanical thrombectomy devices to treat thromboembolism in the venous system. Its product offerings consist of two minimally invasive, catheter-based mechanical thrombectomy systems, which are for venous system and the treatment of the two distinct manifestations of venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE). The Company’s products include ClotTriever System, FlowTriever System, FlowSaver, FlowStasis and FlowTriever 2. The ClotTriever system is a mechanical thrombectomy system designed to core, capture and remove large clots from large vessels and is used to treat DVT and its components include ClotTriever Catheter and ClotTriever Sheath. The FlowTriever is a large bore catheter-based aspiration and mechanical thrombectomy system designed to remove large clots from large vessels to treat PE.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Inari Medical Inc revenues increased 98% to $277M. Net income decreased 29% to $9.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was offset by Selling, general and administrative - Ba increase of 93% to $165.1M (expense), Research and development - Balancing val increase from $17.8M to $48.8M (expense).

Industry: Medical Equipment

6001 Oak Canyon, Suite 100
IRVINE
CALIFORNIA 92618
US

News

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

Cable coils near lows ahead of Fed and BoE rate decisions

It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

14:16, 19 September 2023

FTSE 100 Technical Outlook - 18 September 2023

In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

06:55, 19 September 2023
View of the City of London’s illuminated financial district skyline at dusk

Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

13:46, 15 September 2023

People also watch

Oil - Crude

90.14 Price
+0.770% 1D Chg, %
Long position overnight fee 0.0415%
Short position overnight fee -0.0634%
Overnight fee time 21:00 (UTC)
Spread 0.030

XRP/USD

0.52 Price
+0.700% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

US100

14,710.90 Price
+0.190% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 7.0

ETH/USD

1,598.67 Price
+0.440% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading